Cargando…

Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?

Neurodegenerative diseases, including Parkinson’s disease (PD), are increasing in the aging population. Crucially, neurodegeneration of dopaminergic neurons in PD is associated with chronic inflammation and glial activation. Besides this, bradykinesia, resting tremor, rigidity, sensory alteration, a...

Descripción completa

Detalles Bibliográficos
Autor principal: Gazerani, Parisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787152/
https://www.ncbi.nlm.nih.gov/pubmed/33437512
http://dx.doi.org/10.2144/fsoa-2020-0119
_version_ 1783632771450667008
author Gazerani, Parisa
author_facet Gazerani, Parisa
author_sort Gazerani, Parisa
collection PubMed
description Neurodegenerative diseases, including Parkinson’s disease (PD), are increasing in the aging population. Crucially, neurodegeneration of dopaminergic neurons in PD is associated with chronic inflammation and glial activation. Besides this, bradykinesia, resting tremor, rigidity, sensory alteration, and cognitive and psychiatric impairments are also present in PD. Currently, no pharmacologically effective treatment alters the progression of the disease. Discovery and development of new treatment strategies remains a focus for ongoing investigations. For example, one approach is cell therapy to prevent dopaminergic neuronal loss or to slow PD progression. The neuroprotective role of a diverse range of natural products, including venoms from bees, scorpions, snakes and lizards, are also being tested in preclinical PD models and in humans. The main findings from recent studies that have investigated venoms as therapeutic options for PD are summarized in this special report.
format Online
Article
Text
id pubmed-7787152
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-77871522021-01-11 Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going? Gazerani, Parisa Future Sci OA Special Report Neurodegenerative diseases, including Parkinson’s disease (PD), are increasing in the aging population. Crucially, neurodegeneration of dopaminergic neurons in PD is associated with chronic inflammation and glial activation. Besides this, bradykinesia, resting tremor, rigidity, sensory alteration, and cognitive and psychiatric impairments are also present in PD. Currently, no pharmacologically effective treatment alters the progression of the disease. Discovery and development of new treatment strategies remains a focus for ongoing investigations. For example, one approach is cell therapy to prevent dopaminergic neuronal loss or to slow PD progression. The neuroprotective role of a diverse range of natural products, including venoms from bees, scorpions, snakes and lizards, are also being tested in preclinical PD models and in humans. The main findings from recent studies that have investigated venoms as therapeutic options for PD are summarized in this special report. Future Science Ltd 2020-11-30 /pmc/articles/PMC7787152/ /pubmed/33437512 http://dx.doi.org/10.2144/fsoa-2020-0119 Text en © 2020 Parisa Gazerani This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Special Report
Gazerani, Parisa
Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title_full Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title_fullStr Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title_full_unstemmed Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title_short Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
title_sort venoms as an adjunctive therapy for parkinson’s disease: where are we now and where are we going?
topic Special Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787152/
https://www.ncbi.nlm.nih.gov/pubmed/33437512
http://dx.doi.org/10.2144/fsoa-2020-0119
work_keys_str_mv AT gazeraniparisa venomsasanadjunctivetherapyforparkinsonsdiseasewherearewenowandwherearewegoing